



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : SAEED et al. Confirmation No: Unknown
Appl. No. : 10/718,665
Filed : November 24, 2003
Title : ANTI-PLATELET AGGREGATION COMPOSITIONS

TC/A.U. : Unknown
Examiner : Unknown

Docket No.: : SAE3001/REF
Customer No: : 23364

COMPLETION OF CLAIM FOR PRIORITY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants hereby submit the official certified copy of priority document number GB 0324213.8 in connection with the above identified application, benefit of which is claimed in the declaration of this application. The Examiner is most respectfully requested to acknowledge receipt of this certified copy in the next Official Action.

Respectfully submitted,

BACON & THOMAS, PLLC

By: Richard E. Fichter
Richard E. Fichter
Registration No. 26,382

625 Slaters Lane, 4th Fl.
Alexandria, Virginia 22314
Phone: (703) 683-0500
Facsimile: (703) 683-1080

REF:kdd
Completion of Claim for Priority.wpd

January 12, 2004



INVESTOR IN PEOPLE


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

R. Mahoney
9 December 2003

The
Patent
Office

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference 8.35.81812 16OCT03 E844967-2 000027
POL/7700 0.00 0324213.8

2. Patent application number
(The Patent Office will fill in this part)

0324213.8

3. Full name, address and postcode of the
or of each applicant (underline all surnames)

Sheikh Arshad SAEED and
Shahzada Omar SAEED, both of
3 Glen Rise, Woodford Green,
Essex IG8 0AW, England

Patents ADP number (if you know it)

If the applicant is a corporate body, give
country/state of its incorporation

08696403001
08696411001

4. Title of the invention Anti-Platelet Aggregation Compositions

5. Name of your agent (if you have one) Frank B. Dehn & Co.

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

179 Queen Victoria Street
London
EC4V 4EL

Patents ADP number (if you know it)

166001 ✓

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months	Country	Priority application number (if you know it)	Date of filing (day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)	Number of earlier UK application	Date of filing (day / month / year)

8. Is a Patents Form 7/77 (Statement of
inventorship and of right to grant of a patent)
required in support of this request?

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an
applicant, or
 - c) any named applicant is a corporate body.
- Otherwise answer NO (See note d)

NO

Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form	-
Description	12
Claim(s)	2
Abstract	-
Drawing(s)	3 <i>2 3 4</i>

10. If you are also filing any of the following, state how many against each item.

Priority documents -


Translations of priority documents -

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*) -

Request for a preliminary examination and search (*Patents Form 9/77*) -

Request for a substantive examination (*Patents Form 10/77*) -

Any other documents (please specify) -

11.  I/We request the grant of a patent on the basis of this application.

Signature

Date 15 October 2003

Frank B. Dehn & Co. - Agents for the Applicants

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

J.C. Marsden
020 7206 0600

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s) of the form. Any continuation sheet should be attached to this form.
- If you have answered 'Yes', Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7, you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

81812.622

Anti-Platelet Aggregation Compositions

5 This invention relates to pharmaceutical compositions for application as anti-platelet aggregation agents. In particular, the invention is concerned with the use of compositions comprising aspirin and nimesulide wherein the aspirin is present at a sub-therapeutic dose.

10 Platelet aggregation is involved in a number of cardiovascular disorders (e.g. myocardial infarction and angina) which are a major cause of ill health among the human population. Accordingly a number of different anti-platelet aggregation agents have been investigated
15 for use in the treatment and/or prevention of such diseases.

Platelet aggregation is, however, a poorly understood and complex phenomenon which appears to be associated with a plethora of different metabolic
20 pathways. This is reflected in the fact that a whole range of agonists [e.g. collagen, platelet activating factor (PAF), arachadonic acid (AA), thrombin, adenosine diphosphate (ADP), calcium ionophore (A23187) and epinephrine (epi)] have been shown to induce platelet
25 aggregation. One challenge to be overcome in developing effective anti-platelet aggregation agents is providing a means to effect inhibition of the pathway which has been activated by the agonist present.

One drug which is widely used in anti-platelet
30 aggregation therapy is aspirin (CAS No. 50-78-2). It is sometimes used, for example, in the treatment of unstable angina and myocardial infarction. Aspirin is also believed to be of value in preventing or reducing the risk of second or further adverse cardiovascular
35 events and is commonly prescribed in such a situation for daily intake.

The use of aspirin in combination with a COX II

inhibitor for anti-platelet aggregation has also been disclosed in US-B-6,511,968, where compositions comprising a therapeutically effective amount of aspirin (here given as 75-325 mg) and a therapeutically effective amount of a COX II inhibitor are described for use in treating, preventing or reducing the risk of a number of conditions such as acute coronary ischemic syndrome, thrombosis, thromboembolism, thrombotic occlusion, restenosis, transient ischemic attack and stroke. The rationale behind inclusion of a COX II inhibitor in the anti-platelet aggregation agent is not entirely clear, but the suggestion seems to be that its anti-inflammatory effect is beneficial in reducing the occurrence of adverse cardiovascular events. Thus a huge number of COX II inhibitors of quite disparate structure are mentioned in the patent, though none are exemplified and only the combinations of aspirin with 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone and with 5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(2-methyl-5-pyridyl)pyridine are specifically defined in the claims.

One of the COX II inhibitors mentioned in passing in US-B-6,511,968 is nimesulide (CAS No. 51803-78-2). Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) which is most commonly used in the treatment of inflammatory conditions, fever and/or pain. It has also been reported that nimesulide can function as an anti-platelet aggregation agent (Saeed et al., Biochemical Society Transactions 1998, 26, S342 and Life Sciences 1998, 63(20), pp. 1835-1841). These studies show that nimesulide, and likewise aspirin, inhibit platelet aggregation induced by AA and PAF, and that nimesulide also inhibits platelet aggregation induced by adrenaline.

However, the use of aspirin, whether alone or in combination with a COX II inhibitor, does have potential major drawbacks. The use of therapeutic doses of

aspirin (typically 75 mg or more) is commonly associated with gastro-intestinal disturbances (e.g. nausea, dyspepsia, vomiting) and can also cause gastric mucosal damage such as ulceration. Dizziness, tinnitus, deafness and sweating are also known to occur with larger and/or repeated doses. In extreme cases of aspirin overdose, cardiovascular collapse and respiratory failure may result.

A further problem associated with the use of aspirin in anti-platelet aggregation therapy is that whilst it is effective in inhibiting platelet aggregation induced by AA and PAF, it may be less effective against certain other agonists. Accordingly there is a need for alternative anti-platelet aggregation agents which can provide a broader spectrum of activity (i.e. activity against a wider range of agonists) and which are associated with fewer side effects.

It has now surprisingly been found that the use of aspirin in combination with nimesulide enhances the level of suppression of platelet aggregation relative to the use of either of the agents alone, even when aspirin is used at a sub-therapeutic dose. In particular, an unexpected synergistic effect may be observed between nimesulide and a sub-therapeutic dose of aspirin. This synergistic effect, even at sub-therapeutic doses of aspirin, has significant clinical implications since the use of less aspirin reduces or avoids the side effects associated with this drug, without compromising the therapeutic efficacy achieved. Thus the therapeutic efficacy (i.e. the anti-platelet aggregation effect) of this combination of agents may be enhanced relative to use of either of the agents alone. More particularly, the therapeutic efficacy may be synergistically enhanced.


Thus viewed from one aspect the invention provides a pharmaceutical composition comprising nimesulide and a

sub-therapeutic dose of aspirin, optionally together with one or more pharmaceutically acceptable carriers, excipients and/or diluents.


5 Viewed from a further aspect the invention provides the use of nimesulide and a sub-therapeutic dose of aspirin in the manufacture of a medicament for application as an anti-platelet aggregation agent.

10 Alternatively viewed the invention provides a method of treatment of a human or non-human animal subject in need of anti-platelet aggregation treatment, said method comprising administering to said subject an effective amount of a pharmaceutical composition comprising nimesulide and a sub-therapeutic dose of aspirin.

15 Nimesulide and aspirin for use according to the invention may be obtained from commercial sources, e.g. from Sigma-Aldrich or Cayman Chemicals Co. USA, or may be prepared using standard processes and procedures well known to those skilled in the art. The compounds have
20 the formulae:



Nimesulide



Aspirin

30 Nimesulide is also known as 4'-nitro-2'-phenoxymethanesulphonanilide and N-(4-nitro-2-phenoxyphenyl)methanesulfonamide and the term nimesulide
35 is used herein synonymously with both of these terms.

Aspirin is also known as acetylsalicylic acid, acidum acetylsalicylicum, salicylic acid acetate, o-

acetylsalicylic acid and 2-acetoxybenzoic acid. The term aspirin is used herein synonymously with each of the aforementioned terms.

Side effects of nimesulide are rare and it has generally been found to be well tolerated in a wide range of patients, including elderly and young patients prone to showing side effects with other NSAIDs. Nimesulide has also been tried as a labour-delaying drug and it has been speculated that it may produce fewer adverse side effects on the foetus than other NSAIDs. Use of nimesulide also has the advantage that it is less acidic than many other NSAIDs (pKa 6.5) and has a rapid onset of action.

In preferred compositions of the invention the nimesulide and aspirin may be formulated in a conventional manner with one or more inert carriers, excipients and/or diluents. Examples of carriers, excipients and diluents include water, ethanol, glycerol, polyethylene glycol, sodium chloride, sugars (e.g. glucose, sucrose or lactose), starches (e.g. corn starch or maize starch), microcrystalline cellulose, gums (e.g. gum tragacanth), sorbitol, mannitol, xylitol, magnesium stearate, polyvinylpyrrolidone, fatty acids (e.g. stearic acid), fats, waxes, calcium carbonate, calcium chloride and citric acid.

The compositions may if desired additionally comprise one or more wetting agents, sweetening agents (e.g. a sugar, aspartame or saccharin), lubricating agents, emulsifying agents, suspending agents, preserving agents, flavouring agents (e.g. vanillin, peppermint oil or a fruit flavouring) and/or absorption enhancers.

Preferred compositions of the invention may additionally comprise further (e.g. one or two) pharmaceutically active substances. An advantage associated with the use of a combination of aspirin, nimesulide and further (e.g. one) active substance(s) is

that it may increase the spectrum of diseases for which the composition is suitable for use as a medicament. Additionally or alternatively, an even further lowering of the dose of aspirin and/or the further active
5 substance may advantageously be achieved. This is particularly advantageous if the dose of aspirin which is associated with known above-described side effects can be further reduced.

Additional active substances which may be used in
10 the compositions of the invention include NSAIDs, e.g. COX I and/or COX II inhibitors. Representative COX I and II inhibitors include ibuprofen, mefenamic acid, indomethacin, naproxen, diclofenac salts, paracetamol, N-acetyl-2-aminophenol, N-acetyl-3-aminophenol,
15 rofecoxib, meloxicam, celecoxib, piroxicam, nabumetone, ketoprofen, flusulide, NS-398 and etodolac. In one preferred embodiment the additional active substance may be indomethacin and/or naproxen. Generally, indomethacin may be used in amounts of 1-50 mg per
20 dosage form, in particular about 5-25 mg per dosage form, whilst naproxen may be used in amounts of 10-500 mg per dosage form, for example about 50-250 mg per dosage form.

Other active substances which may be present in the
25 compositions of the invention include vitamins (e.g. vitamin E and in particular vitamin C) and/or CNS stimulants (e.g. caffeine).

The quantity of aspirin present in the compositions of the invention is sub-therapeutic. "Sub-therapeutic"
30 may be considered to be an amount of aspirin which, if administered on its own, would not suffice to achieve a beneficial therapeutic effect (e.g. anti-platelet aggregation). Such an amount may be less than 75 mg, in particular less than 60 mg, e.g. less than 30 mg, per
35 dosage form.

Generally, aspirin may be used in amounts of from 1-60 mg per dosage form, e.g. from 1-50 or 2-50 mg per

dosage form, such as about 5-40 mg per dosage form, in particular about 8-30 mg per dosage form (e.g. about 10 or 15 mg per dosage form). A dosage form may be considered to be one quantum of medicine (e.g. per
5 tablet or per measured amount of liquid). Aspirin may be conveniently used in amounts of from 5-40 wt % of the composition, preferably 10-30 wt %.

The quantity of nimesulide present in the compositions of the invention may be readily determined
10 by those skilled in the art and will depend on several factors, including the method of administration and the weight of the subject. Generally, however, nimesulide may be used in amounts of from 1-200 mg per dosage form, more preferably 5-100 mg per dosage form, in particular
15 about 10-50 mg per dosage form (e.g. 12-25 mg per dosage form, such as about 12 mg per dosage form). In some preferred compositions, the amount of nimesulide present is sub-therapeutic (e.g. less than 100 mg per dosage form, preferably less than 75 mg per dosage form, e.g.
20 about 25 or 12.5 mg per dosage form). Nimesulide may be conveniently used in amounts of from 20-80 wt % of the composition, preferably 40-60 wt %.

In particularly preferred compositions the amount of nimesulide and aspirin present is that required to
25 provide the combination with a therapeutic efficacy which is enhanced relative to use of either of the agents alone. In other words, it is preferred that the combination of nimesulide and aspirin according to the present invention exhibits at least a complementary or
30 additive therapeutic efficacy (i.e. anti-aggregation effect).

Especially preferred combinations of nimesulide and aspirin are those which demonstrate synergistically enhanced therapeutic efficacy. Synergism may result in
35 a therapeutic efficacy which is greater than the additive effect achieved by summation of the use of each of aspirin and nimesulide alone. Synergistic

compositions are particularly advantageous since they allow for the lowering of the dose of aspirin and/or nimesulide (especially of aspirin), and therefore allow for a reduction in the extent and/or frequency of side effects to be achieved.

Representative examples of compositions exhibiting a synergistically enhanced therapeutic efficacy comprise 1-60 mg aspirin and 1-200 mg nimesulide, preferably 1-50 mg aspirin and 5-100 mg nimesulide, more preferably 8-30 mg aspirin and 10-50 mg nimesulide, e.g. 10-15 mg aspirin and 12-25 mg nimesulide, typically 10 mg aspirin and 12.5 mg nimesulide.

It will also be appreciated that the aspirin and the nimesulide need not be provided in the same composition in order for their synergistic effect to be achieved *in vivo*. Thus the sub-therapeutic dose of aspirin and the dose of nimesulide may alternatively be provided in separate preparations which are administered either simultaneously or sequentially.

Thus viewed from a further aspect the invention provides a preparation comprising nimesulide and, separately, a sub-therapeutic dose of aspirin, for simultaneous or sequential use as an anti-platelet aggregation agent. In preferred preparations, the doses of nimesulide and aspirin present are as hereinbefore described in relation to pharmaceutical compositions of the invention.

The compositions and preparations according to the invention may be administered orally, rectally (e.g. using a suppository), topically or systemically. The route chosen will depend, for example, on the subject to be treated. Preferably the compositions and preparations according to the invention are administered orally.

The compositions and preparations of the invention may be presented in any form adapted for use in the administration route selected. Forms suitable for

systemic administration may, for example, be formulations for intradermal, intraperitoneal or intravenous injection or infusion.

5 Forms adapted for topical administration include compositions for administration to the skin and mucosa (e.g. gels, creams, sprays, lotions, salves and aerosols).

10 Forms suitable for oral administration include, for example, plain or coated tablets, sustained release tablets, chewable tablets, soft capsules, hard capsules, suspensions and syrups. Preferred forms for use according to the invention are tablets, suspensions or syrups, particularly tablets.

15 Compositions and preparations of the present invention are preferably in a ready to use form. Alternatively the composition or preparations may be provided in a concentrate form which is mixed with a liquid (e.g. hot water) immediately prior to use.

20 Compositions and preparations of the invention may also be in forms adapted to permit slow release of nimesulide. This may, for example, be achieved through encapsulation of the nimesulide content in biodegradable polymer microparticles or microsphere delivery systems.

25 The compositions hereinbefore described are suitable for the therapeutic or prophylactic treatment of cardiovascular disorders. A cardiovascular disorder may be considered to be a condition of the heart, arteries or veins which disrupts the supply of oxygen to life-sustaining areas of the body such as the brain, the heart, etc. Examples of cardiovascular disorders
30 include angina pectoris, stroke, myocardial infarction, arteriosclerosis, arrhythmia and thrombosis (including thrombosis induced by surgery). Preferably, the compositions of the invention are used for the
35 prophylactic treatment of cardiovascular disorders (e.g. myocardial infarction).

All preferred features of the compositions

hereinbefore described are also preferred features of medicaments produced using of nimesulide and aspirin in accordance with the present invention. Thus the invention also provides use of nimesulide and a sub-
5 therapeutic dose of aspirin in the manufacture of a medicament for treatment of any of the above-mentioned diseases.

Furthermore, all preferred features of the preparations hereinbefore described are also preferred
10 features of preparations manufactured using nimesulide and aspirin in accordance with the invention. Consequently use of nimesulide and, separately, a sub-therapeutic dose of aspirin in the manufacture of a preparation as hereinbefore defined for simultaneous or
15 sequential use as an anti-platelet aggregation agent forms a further aspect of the invention.

The invention will now be described in more detail by way of the following non-limiting Example:

EXAMPLE

Anti-platelet aggregation action of aspirin and
nimesulide

5 In a randomized observer-blinded crossover study
with a 2 week washout period, young age-matched male
volunteers (n = 34) took a single dose of (i) aspirin
(10, 20 or 40 mg), (ii) nimesulide (5, 12.5, 25 or 50
10 mg) or (iii) aspirin and nimesulide (10 mg and 12.5 mg
respectively), with a 250 ml glass of water, on an empty
stomach. 10 ml blood samples were taken, by vein
puncture, just prior to, and 24 hours after, drug
ingestion, and the samples were mixed with 3.8% w/v
sodium citrate solution (9:1) and centrifuged at 260 g
15 for 15 minutes at 20°C to obtain platelet rich plasma
(PRP).

 The PRP samples were treated *in vitro* with calcium
ionophore (A23187, 2.5 μ M) or arachidonic acid (AA,
1.6 mM) to induce maximal aggregation. Platelet
20 aggregation was monitored using a Dual-channel Lumi-
aggregometer (Model 400, Chronolog Corporation, USA)
using 0.45 ml samples of PRP. The resulting aggregation
was recorded for all of the samples and a comparison was
made between the pre- and post-test drug ingestion
25 aggregation levels. The data was analysed using the
Student's t-test and differences were considered
significant when probability (p) was <0.05.

 The results of the *ex vivo* study show that both
aspirin and nimesulide inhibit platelet aggregation
30 induced by AA or A23187 in a concentration dependent
manner. At a dose of 20 mg or 40 mg, aspirin
effectively inhibited platelet aggregation induced by
either agonist, whereas at a concentration of 10 mg,
aspirin was only weakly effective (about 25% inhibition)
35 against platelet aggregation induced by A23187 and was
ineffective against AA (see Figure 1).

 Nimesulide, at doses of 25 or 50 mg, also

effectively inhibited platelet aggregation induced by AA and A23187, but only effected approximately 30% inhibition against each agonist at a dose of 12.5 mg (see Figure 2).

5 The results obtained from use of aspirin and nimesulide in combination are startling (see Figure 3). The use of 10 mg of aspirin and 12.5 mg of nimesulide in combination was found to inhibit platelet aggregation induced by AA and A23187 at levels of approximately 85%
10 and 75% respectively. Thus, use of nimesulide and aspirin as a combination leads to synergistically enhanced therapeutic efficacy relative to the use of either compound alone. This is further illustrated by Table 1 below.

15

Table 1:

Anti-Platelet Aggregation Effect of Aspirin, Nimesulide and a combination thereof *In Vivo*

20

	% Inhibition AA	% Inhibition A23187
Aspirin 10 mg	4	27
Nimesulide 12.5 mg	28	32
Additive effect (of aspirin and nimesulide)	32	59
25 Actual effect (of aspirin and nimesulide)	85	75

Claims

1. A pharmaceutical composition comprising nimesulide and a sub-therapeutic dose of aspirin, optionally
5 together with one or more pharmaceutically acceptable carriers, excipients and/or diluents.
2. A composition as claimed in claim 1 for application as an anti-platelet aggregation agent.
10
3. A composition as claimed in claim 2 wherein the anti-aggregation effect of said nimesulide and said aspirin is enhanced relative to use of either of nimesulide or aspirin alone.
15
4. A composition as claimed in claim 2 wherein the anti-aggregation effect of said nimesulide and said aspirin is synergistic.
- 20 5. A composition as claimed in any preceding claim wherein said sub-therapeutic dose of aspirin is 1-60 mg per dosage form.
- 25 6. A composition as claimed in any preceding claim wherein said nimesulide is present in an amount of 1-200 mg.
- 30 7. A composition as claimed in any one of claims 1 to 5 wherein said nimesulide is present in a sub-therapeutic amount.
- 35 7. Use of nimesulide and a sub-therapeutic dose of aspirin in the manufacture of a medicament for application as an anti-platelet aggregation agent.
8. A method of treatment of a human or non-human animal subject in need of anti-platelet aggregation

treatment, said method comprising administering to said subject an effective amount of a pharmaceutical composition or preparation comprising nimesulide and a sub-therapeutic dose of aspirin.

5

9. A preparation comprising nimesulide and, separately, a sub-therapeutic dose of aspirin, for simultaneous or sequential use as an anti-platelet aggregation agent.

10

10. Use of nimesulide and, separately, a sub-therapeutic dose of aspirin in the manufacture of preparations for simultaneous or sequential use as an anti-platelet aggregation agent.

1000000
1000000
1000000

Aspirin




Figure 1

Nimsulide




Figure 2

Aspirin 10mg + Nimsulide 12.5mg




Figure 3